Truist Financial
BMRN icon

Truist Financial’s BioMarin Pharmaceuticals BMRN Stock Holding History

Truist Financial’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,333
Closed -$378K – 2654
2024
Q1 		$378K Sell
4,333
-2,348
-35% -$210K ﹤0.01% 2161
2023
Q4 		$644K Buy
6,681
+1,067
+19% +$94.4K ﹤0.01% 1830
2023
Q3 		$497K Buy
5,614
+1,624
+41% +$144K ﹤0.01% 1930
2023
Q2 		$346K Sell
3,990
-1,045
-21% -$98.3K ﹤0.01% 2171
2023
Q1 		$490K Buy
5,035
+534
+12% +$55.4K ﹤0.01% 1990
2022
Q4 		$466K Buy
4,501
+448
+11% +$42.1K ﹤0.01% 2011
2022
Q3 		$344K Buy
4,053
+242
+6% +$21.5K ﹤0.01% 2015
2022
Q2 		$316K Sell
3,811
-827
-18% -$65.8K ﹤0.01% 2185
2022
Q1 		$358K Sell
4,638
-3,487
-43% -$292K ﹤0.01% 2196
2021
Q4 		$718K Sell
8,125
-2,913
-26% -$240K ﹤0.01% 1818
2021
Q3 		$853K Buy
11,038
+2,488
+29% +$196K ﹤0.01% 1699
2021
Q2 		$713K Sell
8,550
-3,001
-26% -$238K ﹤0.01% 1834
2021
Q1 		$873K Sell
11,551
-1,953
-14% -$160K ﹤0.01% 1670
2020
Q4 		$1.18M Sell
13,504
-6,828
-34% -$541K ﹤0.01% 1392
2020
Q3 		$1.55M Buy
+20,332
New +$2.06M ﹤0.01% 1176
2020
Q2 		– Sell
-111,158
Closed -$9.39M – 2423
2020
Q1 		$9.39M Buy
111,158
+93,218
+520% +$8.03M 0.02% 502
2019
Q4 		$1.52M Buy
17,940
+6,426
+56% +$485K ﹤0.01% 1258
2019
Q3 		$776K Sell
11,514
-1,024
-8% -$78.9K 0.01% 495
2019
Q2 		$1.07M Sell
12,538
-2,063
-14% -$176K 0.02% 442
2019
Q1 		$1.3M Sell
14,601
-569
-4% -$52.7K 0.02% 425
2018
Q4 		$1.29M Sell
15,170
-923
-6% -$87.8K 0.03% 410
2018
Q3 		$1.56M Buy
16,093
+1,100
+7% +$110K 0.03% 407
2018
Q2 		$1.41M Buy
14,993
+62
+0.4% +$5.43K 0.03% 410
2018
Q1 		$1.21M Buy
14,931
+302
+2% +$25.9K 0.02% 441
2017
Q4 		$1.3M Buy
14,629
+16
+0.1% +$1.39K 0.02% 438
2017
Q3 		$1.36M Buy
14,613
+1,835
+14% +$162K 0.03% 421
2017
Q2 		$1.16M Buy
12,778
+226
+2% +$20.6K 0.02% 446
2017
Q1 		$1.1M Buy
12,552
+1,016
+9% +$90.4K 0.02% 453
2016
Q4 		$955K Sell
11,536
-121
-1% -$10.4K 0.02% 479
2016
Q3 		$1.08M Sell
11,657
-642
-5% -$60.5K 0.02% 458
2016
Q2 		$957K Buy
12,299
+650
+6% +$55.3K 0.02% 482
2016
Q1 		$961K Buy
11,649
+3,352
+40% +$273K 0.02% 438
2015
Q4 		$870K Buy
8,297
+1,382
+20% +$144K 0.02% 438
2015
Q3 		$728K Buy
6,915
+1,174
+20% +$157K 0.02% 470
2015
Q2 		$785K Buy
5,741
+1,666
+41% +$206K 0.02% 432
2015
Q1 		$508K Buy
4,075
+792
+24% +$83.9K 0.01% 523
2014
Q4 		$297K Sell
3,283
-149
-4% -$12.4K 0.01% 635
2014
Q3 		$247K Buy
+3,432
New +$226K 0.01% 675

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Truist Financial's BMRN Position: Q2 2024 in Review

Truist Financial sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 4,333 shares — an estimated $378K sold.

Truist Financial first reported a position in BMRN in Q3 2014 and held it in 38 quarters. The position peaked at $9.39M in Q1 2020. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

  • Truist Financial reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Truist Financial sold 4,333 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $378K.
  • Truist Financial first reported a position in BioMarin Pharmaceuticals in Q3 2014 and held it in 38 quarters.
  • Truist Financial's BioMarin Pharmaceuticals position peaked at $9.39M in Q1 2020.
  • 558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on Truist Financial's 13F filing for Q2 2024, filed 21 Aug 2024.